EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens

Simiso Sokhela iD, Willem D F Venter iD, Bronwyn Bosch, Joana Woods, Kaitlyn McCann, Godspower Akpomiemie, Nomathemba Chandiwana, Nkuli Mashabane, Angela Tembo, Bryony Simmons, Samanta Lalla-Edward, Mark J Siedner und 14 weitere

Open Forum Infectious Diseases · 29.02.2024 · 11 (3)

DOI: 10.1093/ofid/ofae007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 24.01.2024. Verfasst von Simiso Sokhela und 25 weiteren Autor:innen. Beteiligte Einrichtung: Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Unitaid, USAID, South African Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ADVANCE compared 3 World Health Organization–recommended first-line regimens in participants with HIV who were antiretroviral naive.

Methods

This randomized, open-label, noninferiority trial enrolled participants living with HIV with no antiretroviral exposure in the previous 6 months to 1 of the following arms: tenofovir alafenamide (TAF) / emtricitabine (FTC) + dolutegravir (DTG) (2 tablets), tenofovir disoproxil fumarate (TDF) / FTC + DTG (2 tablets), or a fixed-dose combination of TDF / FTC / efavirenz (EFV) (1 tablet). We report the final safety and efficacy data up to 192 weeks.

Results

Repeat consent from the original 351 participants randomized to each arm was obtained from 230 participants (66%) in the TAF/FTC + DTG arm, 209 (60%) in the TDF/FTC + DTG arm, and 183 (52%) in the TDF/FTC/EFV arm. At 192 weeks, 213 (61%) of the original 351 participants in the TAF/FTC + DTG arm, 195 (56%) in the TDF/FTC + DTG arm, and 172 (49%) in the TDF/FTC/EFV arm had confirmed RNA <50 copies/mL, with low virologic failure in all groups and no significant integrase inhibitor mutations in any arm. Mean weight gain was 8.9 kg (SD, 7.1) in the TAF/FTC + DTG arm, 5.9 kg (SD, 7.1) in the TDF/FTC + DTG arm, and 3.2 kg (SD, 8.1) in the TDF/FTC/EFV arm at 192 weeks from baseline and was greatest among women, those taking TAF, and those with lower baseline CD4 counts. The weight trajectory slowed after week 96. There were few clinical events and minor laboratory changes and differences among arms after 96 weeks. There were no significant differences in treatment-emergent hypertension or pregnancy outcomes by arm.

Conclusions

High viral suppression was seen across arms, with no resistance to DTG. Weight gain continued but slowed after 96 weeks, with few clinical events or laboratory changes.

Schlagwörter

Stichwörter der Autor:innen

dolutegravirobesityresistancesuppressiontenofovir

Autor:innen und Institutionen

  • Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • School of Public Health, Imperial College London, London, UK.
  • LSE Health, London School of Economics and Political Science, Imperial College London, London, UK.
  • Africa Health Research Institute, KwaZulu-Natal, South Africa.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Simiso Sokhela, Willem D F Venter

Förderung

  • Unitaid
  • USAID
  • South African Medical Research Council
  • ViiV Healthcare
  • Gilead Sciences

Zitieren

APA

Sokhela, S., Venter, W. D. F., Bosch, B., Woods, J., McCann, K., Akpomiemie, G., Chandiwana, N., Mashabane, N., Tembo, A., Simmons, B., Lalla-Edward, S., Siedner, M. J., Sinxadi, P., Hermans, L., Fairlie, L., Vos, A., Abrams, E., Manne-Goehler, J. M., Moorhouse, M., …, & Hill, A. (2024). Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infectious Diseases, 11(3). https://doi.org/10.1093/ofid/ofae007

Vancouver

Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, et al. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infectious Diseases. 2024;11(3). doi:10.1093/ofid/ofae007

BibTeX
@article{Sokhela2024,
  author = {Sokhela, Simiso and Venter, Willem D F and Bosch, Bronwyn and Woods, Joana and McCann, Kaitlyn and Akpomiemie, Godspower and Chandiwana, Nomathemba and Mashabane, Nkuli and Tembo, Angela and Simmons, Bryony and Lalla-Edward, Samanta and Siedner, Mark J and Sinxadi, Phumla and Hermans, Lucas and Fairlie, Lee and Vos, Alinda and Abrams, Elaine and Manne-Goehler, Jennifer M and Moorhouse, Michelle and Clayden, Polly and Norris, Shane and Qavi, Ambar and Chersich, Matthew and Masenya, Masebole and Arulappan, Natasha and Hill, Andrew},
  title = {Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens},
  journal = {Open Forum Infectious Diseases},
  year = {2024},
  volume = {11},
  number = {3},
  doi = {10.1093/ofid/ofae007}
}
Kostenlos starten →